Ads Running throughout the City Are Alerting New Yorkers that a Major Cancer is Now Preventable

Released on: October 28, 2008, 9:52 am

Press Release Author: OralCDx

Industry: Healthcare

Press Release Summary: "So Disfiguring, So Preventable", the Message about Oral
Cancer that is Dominating the City

Press Release Body: NEW YORK - October 28, 2008 - Preventing oral cancer is the word
on the street in New York City, as scores of people are spotting advertisements that
are running on hundreds of city buses, inside and out. Oral cancer, which kills
twice as many Americans as cervical cancer, is now especially on the rise in young
people, women and non-smokers partly due to what is widely suspected to be an oral
sex related increase in exposure to the human papilloma virus (HPV). OralCDx
Laboratories, a division of Oral Cancer Prevention International, has launched a bus
ad campaign, urging people to visit BrushTest certified dentists for this routine
screening test. The BrushTest, often compared to the Pap smear for the prevention
of cervical cancer, tells patients if any of the common red and white spots that are
found in almost everyone's mouth at one time or another are pre-cancerous and need
to be removed, long before they have the chance to develop into cancer.

The ad appears on the outside and inside of 450 MTA buses. Simultaneously, a
similar ad jointly placed by OralCDx Laboratories and the American Dental
Association is running on over 100 MTA buses.

The bus ads will be running until the end of November, leading into the Greater New
York Dental Meeting, taking place at The Javits Center starting on November 28.

Oral cancer, one of the most disfiguring cancers, kills about as many Americans as
melanoma and twice as many as cervical cancer. Very few cancers are preventable,
and OralCDx is on a mission to let people know that oral cancer has recently joined
the short list of preventable cancers. The effectiveness and accuracy of the
BrushTest is referenced by both the National Cancer Institute and the ADA, and the
test is used by over 30,000 dentists nationwide.

About the BrushTest

OralCDx Laboratories, a division of Oral Cancer Prevention International, Inc., is
the worldwide, exclusive provider of the BrushTest, utilizing patented and
proprietary tissue sampling and cell analysis systems. The BrushTest is used by
dentists and physicians to help prevent oral cancer, a disease that kills as many
Americans as melanoma, twice as many as cervical cancer, and is rising among women,
young people and non-smokers. Well over 25% of those found to have oral cancer do
not use tobacco or abuse alcohol. Recent studies have also shown a link between HPV
and an increase in oral cancer.

The BrushTest is taught in the majority of U.S. dental schools and is a covered
benefit under Medicare, Medicaid and most private U.S. medical and dental insurance
plans. The American Dental Association (ADA), in collaboration with OralCDx
Laboratories, has recently embarked on a campaign to inform patients that because of
the BrushTest, oral cancer has joined the short list of cancers that can now be
stopped, years before they can even start. The accuracy of OralCDx was demonstrated
in one of the largest studies in oral medicine ever conducted, performed at 35
academic centers in the U.S., involving nearly 1,000 patients. This study was
published as the cover story of the Journal of the American Dental Association and
earned OralCDx the ADA's prestigious Seal of Acceptance.

For more information on the OralCDx BrushTest, call (877) 672-5722 or visit

Web Site:

Contact Details: Sharon Golubchik

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...